GB:0RAD Stock Latest News
Company AnnouncementsOSE Immunotherapeutics’ Tedopi Combo Shows Survival Gain in Lung Cancer Phase 2 Trial4d ago
Company AnnouncementsOSE Immunotherapeutics’ Tedopi Combo Shows Survival Gain in Phase 2 NSCLC Trial2w ago
Company AnnouncementsOSE Immunotherapeutics to Present at Chardan Healthcare Conference in New York2w ago
Company AnnouncementsOSE Immunotherapeutics Updates Share Capital and Voting Rights Structure3w ago
Company AnnouncementsOSE Immunotherapeutics Extends Cash Runway as Tedopi and Lusvertikimab Advance in Late-Stage Trials1M ago
Company AnnouncementsOSE Immunotherapeutics’ Tedopi Lung Cancer Trial Selected for Oral Presentation at ESMO 20261M agoCompany AnnouncementsOSE Immunotherapeutics’ Partner Veloxis Starts Phase 2 Trial of Transplant Drug Pegrizeprument1M ago
Company AnnouncementsOSE Immunotherapeutics Updates Share Capital and Voting Rights After New Share Issuance1M ago
Company AnnouncementsOSE Immunotherapeutics Showcases Lead IBD Drug Lusvertikimab in Upcoming KOL Webcast2M ago
Company AnnouncementsOSE Immunotherapeutics Updates Share Capital and Voting Rights After New Equity Issuance2M ago
